Want to see MIST full AI Analyst Report?
MIST Stock Chart & Stats
$1.16
-$0.03(-2.59%)
At close: 4:00 PM EDT
$1.16
-$0.03(-2.59%)
Day’s Range― - ―
52-Week Range$1.00 - $3.06
Previous Close$1.14
Volume1.21M
Average Volume (3M)1.21M
Market Cap
$143.17M
Enterprise Value$108.15
Total Cash (Recent Filing)$184.22M
Total Debt (Recent Filing)$137.33M
Price to Earnings (P/E)―
Beta2.74
Next Earnings
Aug 12, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.68
Shares Outstanding124,497,980
10 Day Avg. Volume819,423
30 Day Avg. Volume1,214,359
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)4.06
Price to Sales (P/S)109.60
P/FCF Ratio-3.43
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.50Price Target Upside546.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.85
Revenue Forecast (FY)$5.39M
Bulls Say, Bears Say
Bulls Say
Strong Cash RunwayMilestone’s ~$184M cash balance funds the CARDAMYST launch and initiation of ReVeRa‑301 into H2 2027. This sizeable runway reduces near-term financing pressure, allowing focused commercial rollout and trial execution without immediate dilution risk if burn stays near plan.
Early Commercial TractionRapid prescription uptake and multi-prescriber breadth indicate meaningful early demand and effective rep engagement. Structural adoption by many unique HCPs supports scalable prescribing potential if payer access and patient activation progress, underpinning durable commercial growth prospects.
Major Payer Validation — Express ScriptsInclusion on a large national formulary provides structural access to a meaningful share of commercial lives. This early payer acceptance materially improves long-term patient access and refill economics, forming a durable foundation for scaling outpatient, self-administered therapy adoption.
Bears Say
High LeverageDebt-to-equity near 3.8x is elevated for a loss-making biotech, constraining financial flexibility. High leverage heightens refinancing and covenant risk, increases interest burdens, and raises the likelihood of future dilution if clinical or commercial outcomes falter, eroding long-term stability.
Persistent Cash BurnSustained negative operating and free cash flow shows the business depends on external funding absent material product revenue. Ongoing high burn will steadily consume runway and could force dilutive financing or spending cuts before commercial revenue scales, limiting long-term optionality.
Very Limited Current Product RevenueEarly prescriptions have not yet translated into meaningful sales; refill depth and Medicare coverage remain limited. Structural revenue generation is unproven, so sustained commercial performance hinges on broader payer contracts, patient activation and repeat use to support margins and offset burn.
Milestone Pharmaceuticals News
MIST FAQ
What was Milestone Pharmaceuticals’s price range in the past 12 months?
Milestone Pharmaceuticals lowest stock price was $1.00 and its highest was $3.06 in the past 12 months.
What is Milestone Pharmaceuticals’s market cap?
Milestone Pharmaceuticals’s market cap is $143.17M.
When is Milestone Pharmaceuticals’s upcoming earnings report date?
Milestone Pharmaceuticals’s upcoming earnings report date is Aug 12, 2026 which is in 10 days.
How were Milestone Pharmaceuticals’s earnings last quarter?
Milestone Pharmaceuticals released its earnings results on May 13, 2026. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of $0.19 by -$0.39.
Is Milestone Pharmaceuticals overvalued?
According to Wall Street analysts Milestone Pharmaceuticals’s price is currently Undervalued.
Does Milestone Pharmaceuticals pay dividends?
Milestone Pharmaceuticals does not currently pay dividends.
What is Milestone Pharmaceuticals’s EPS estimate?
Milestone Pharmaceuticals’s EPS estimate is -0.2.
How many shares outstanding does Milestone Pharmaceuticals have?
Milestone Pharmaceuticals has 124,497,980 shares outstanding.
What happened to Milestone Pharmaceuticals’s price movement after its last earnings report?
Milestone Pharmaceuticals reported an EPS of -$0.2 in its last earnings report, missing expectations of $0.19. Following the earnings report the stock price went down -9.474%.
Which hedge fund is a major shareholder of Milestone Pharmaceuticals?
Currently, no hedge funds are holding shares in MIST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Milestone Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.50 (546.55% Upside)
$7.50 (546.55% Upside)
Blogger Sentiment
Bullish
MIST Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 133.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.11%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
213.05%
Trailing 12-Months
Company Description
Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate. Furthermore, Milestone Pharmaceuticals has forged a licensing and collaboration alliance with Ji Xing Pharmaceuticals to advance and distribute etripamil for both preventative and therapeutic applications in humans. The company was founded in 2003.
MIST Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly positive early-launch narrative: Milestone executed a rapid launch, secured an important Express Scripts formulary placement, achieved early prescriber breadth (≈400 writers) and initiated a Phase III AFib-RVR program, while ending the quarter with a strengthened cash position (~$184M) and a planned, ROI-driven commercial strategy. Offsetting these positives are very small product revenues ($0.2M), elevated launch-driven commercial spend (+51.9% YoY), an increased quarterly net loss (~+25.5% YoY) and continued operating cash burn (~$23.7M in Q1). Coverage remains limited (~25% commercial) and scale/refill dynamics are in the earliest stages, so near-term sales will likely remain modest until broader payer coverage, patient activation and increased promotional frequency deliver deeper adoption.View all MIST earnings summariesMIST Stock 12 Month Forecast
Average Price Target
$7.50
▲(546.55% Upside)
Technical Analysis
Corbus Pharmaceuticals
―
Seres Therapeutics
―
Avalo Therapeutics
―
Elicio Therapeutics
―
Alto Neuroscience, Inc.
―
Ownership Overview
0.88% Insiders
0.06% Mutual Funds
2.95% Other Institutional Investors
93.40% Public Companies and
Individual Investors